Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension | Zendy

ZhiCheng Jing | Zendy; Keyur Parikh | Zendy; Tomás Pulido | Zendy; Carlos JerjesSánchez | Zendy; R. James White | Zendy; Roblee P. Allen | Zendy; Adam Torbicki | Zendy; Kai-Feng Xu | Zendy; David Yehle | Zendy; Kevin Laliberte | Zendy; Carl Arneson | Zendy; Lewis J. Rubin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension

Author(s) -

ZhiCheng Jing,

Keyur Parikh,

Tomás Pulido,

Carlos JerjesSánchez,

R. James White,

Roblee P. Allen,

Adam Torbicki,

Kai-Feng Xu,

David Yehle,

Kevin Laliberte,

Carl Arneson,

Lewis J. Rubin

Publication year - 2013

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.112.124388

Subject(s) - treprostinil , medicine , pulmonary hypertension , cardiology , intensive care medicine

Pulmonary arterial hypertension (PAH) is a progressive, fatal disease with no cure. Parenteral and inhaled prostacyclin analogue therapies are effective for the treatment of PAH, but complicated administration requirements can limit the use of these therapies in patients with less severe disease. This study was designed to evaluate the safety and efficacy of the oral prostacyclin analogue treprostinil diolamine as initial treatment for de novo PAH.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research